Objetivou-se avaliar o desempenho produtivo de bovinos Nelore e suas cruzas com Blonde d'Aquitaine (½ Nelore + ½ Blonde d'Aquitaine) do nascimento ao desmame, mantidos em sistema de pastejo, no Estado de Alagoas. Foram analisadas 1.279 medidas de peso ao nascimento (PN) e peso à desmama ajustado para 210 dias (P210) referentes ao período entre os anos de 2005 e 2010. Utilizou-se o delineamento inteiramente casualizado, adotando-se um nível de significância de 5%. Os pesos médios para PN e P210 foram respectivamente 31,60kg e 158,66kg, para os animais Nelore, e 33,05kg e 167,03kg, para os animais cruzados. Não houve interação (P<0,05) entre grupo genético e sexo do animal, para nenhuma variável analisada. Foram observados efeitos significativos do grupo genético, sexo e época de nascimento (P<0,05) sobre PN. O grupo genético e o sexo foram significativos sobre o P210. O efeito de época de nascimento foi significativo no peso ao nascimento, mas não houve efeito no P210, provavelmente devido à variação climática verificada na região. Animais machos apresentaram pesos superiores (P<0,05) evidenciando o dimorfismo sexual. Os animais cruzados são superiores aos da raça Nelore em todas as características consideradas, proporcionando, inclusive, bezerros mais pesados ao nascimento, sem, no entanto, apresentar partos distócicos. Os animais cruzados também são adequados em relação à grande adaptação às condições climáticas e de manejo às quais foram submetidos, constituindo-se uma excelente opção para cruzamentos na região Nordeste, em condições ambientais semelhantes às deste estudo.

A case of lissencephaly and cerebellar hypoplasia was observed in a 30

This work aims to compare the occurrence of negative emotion words in Brazilian broadcast news JN and JR, and also analyzes Twitter posts related to them. We use the Brazilian Portuguese version of LIWC dictionary, which is a Sentiment Analysis software. The results indicate that both JN and JR tend to use negative emotion words, but in JR this tendency is greater. Nevertheless, Twitter posts direct more criticisms towards JN than JR.

IntroductionThe development of health technology assessment (HTA) reports is a time-consuming process that requires highly trained human resources. In many Latin American countries this type of personnel is scarce. The adaptation of HTA could be a time-saving process to get inputs for decision. The objective of this study is to determine the frequency of use of HTA adaptation process and to describe type of tools used in this process in Latin American countries.MethodsThe Health Technology Assessment Network of the Americas (REDETSA) is a non-profit network formed by ministries of health, regulatory authorities and health technology assessment agencies (PAHO/WHO). During the last meeting of REDETSA in November 2018, we performed an exploration survey to gather information related to the topic in order to promote the creation of an adaptation working group. The question was whether HTA agencies did adaptation of HTA reports and, if so, what methods and tools were used and what sections of the report were adapted.ResultsThirty-three institutions from fourteen Latin American countries answered to the consultation. Seven countries do adaptation of HTA (50 percent) and one country does adoption. Of those countries that adapt HTA, three do only economic transferability. Methods and tools are usually developed locally or there is not a systematic approach. In two countries, the economic study transferability tool developed by Hutter and Antoñaza is used.ConclusionsAdaptation of HTA is not well developed among Latin American agencies, although it seems to be an efficient strategy when assessing efficacy and safety. Adaptation of economic studies is still controversial; nevertheless, it is used in some of the countries of the region. It is necessary to advance in the development of HTA adaptation tools, developed and adapted to local contexts in the region.

Introduction:Vemurafenib plus cobimetinib (VC) for the treatment of metastatic melanoma was requested to be included in the National Formulary in Uruguay. The standard of care for metastatic melanoma in Uruguay is dacarbazine. There is no published head-to-head trial assessing the effects of VC versus dacarbazine. The objective of this study was to perform an indirect comparison of the effects of dacarbazine, compared with VC, based on the results of trials that included both treatments versus the same comparator (vemurafenib alone).Methods:We searched Pubmed and The Cochrane Library for trials comparing either VC or dacarbazine with vemurafenib. Trials were assessed in terms of risk of bias, similarity of interventions and inclusion and exclusion criteria, and comparability of characteristics of patients in the vemurafenib arm. We performed an indirect comparison using the Bucher method.Results:From the literature search we retrieved two studies that met the inclusion criteria: a randomized clinical trial that assessed VC versus vemurafenib or placebo and another assessing dacarbazine versus vemurafenib. Both studies were similar in terms of methodological quality, inclusion and exclusion criteria, and comparability of the vemurafenib arms. However, the comparison of overall survival and progression-free survival curves for the vemurafenib arms were quite different between the two trials. At 9 months, overall survival was eighty-one percent and fifty-five percent and progression-free survival was thirty percent and fifteen percent, respectively. The indirect comparison provided the following hazard ratios: 0.24 (95% confidence interval [CI]: 0.14–0.48) for overall survival; 0.13 (95% CI: 0.09–0.19) for progression-free survival; and 0.15 (95% CI: 0.02–1.29) for grade 4 adverse events.Conclusions:Treatment with VC increased overall survival and progression-free survival, compared with dacarbazine. Severe adverse events were less frequent with the combined therapy. However, the differences in the vemurafenib survival curves increases doubts about the accuracy of the indirect estimators of overall survival and progression-free survival.